Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Drug interactions and pharmacokinetics
Prezista (darunavir) label change - drug interaction information

The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine. The specific changes are outlined below.

Published
02 March 2013
From
US Food and Drug Administration
Treatment guidelines
Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection

Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART. The guidelines continue to recommend treatment for all people with HIV, both to reduce the risk of disease progressionand for the prevention of HIV transmission.

Published
15 February 2013
From
HIVandHepatitis.com
Hepatitis C treatment side-effects
Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

Published
15 February 2013
From
CATIE
Treatment guidelines
Updated U.S. DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

New recommendations on drug-resistance testing, genotypic tropism assays, starting treatment, acute infection, pregnancy and interactions.

Published
15 February 2013
From
AIDSinfo
Drug interactions and pharmacokinetics
Certain Meds Mixed With Grapefruit Juice Can Be a Fatal Cocktail

The scientist who discovered that grapefruit can alter  drug levels in the body has released an updated list of 85 medications that may cause such reactions, in order to reflect releases of new medications over the past four years.

Published
21 December 2012
From
AIDSMeds
Drug interactions and pharmacokinetics
Mistakes are still commonly made in prescriptions of antiretroviral medications

Research presented at IDWeek 2012- concludes that despite advances in electronic medical records, mistakes are still commonly made in the prescription of antiretroviral medications for hospitalized HIV-positive patients. At the same time, a trio of studies suggests however, that electronic records in combination with increased clinical education can help to greatly decrease medical errors.

Published
22 October 2012
From
News Medical
TB treatment
Tuberculosis: Combined wisdom

Buried in the HIV frenzy at the International AIDS Conference was a rather important announcement for another blight, tuberculosis.

Published
26 July 2012
From
The Economist
HIV treatment in children
Efavirenz Works in Kids with Both HIV and TB

Children co-infected with HIV and tuberculosis appear to suppress both infections when treated with standard TB regimens and an efavirenz-based HIV regimen, researchers said here at the International AIDS Conference.

Published
25 July 2012
From
MedPage Today HIV/AIDS
New and experimental HIV treatments
Similar Efficacy, Side Effects in Study of Gilead Booster Cobicistat and Norvir

Compared with Norvir (ritonavir), people living with HIV using Gilead Sciences’ novel boosting agent cobicistat were just as likely to see their viral loads drop to undetectable levels and no more likely to discontinue therapy due to side effects, according to preliminary results from a Phase III study comparing both drugs in combination with Reyataz (atazanavir) and Truvada (tenofovir plus emtricitabine).

Published
25 July 2012
From
AIDSMeds
TB treatment
UCSF/SFGH Researchers Call for Change in New FDA Recommendation on HIV and TB Drug Doses

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB). Now, a new analysis by the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH) suggests this recommended dose adjustment may not be necessary, particularly in non-Caucasian populations.

Published
24 July 2012
From
USCF News Center
← First123...4Next →

Filter by country